Table 3. K AV , B max , and IC 50 of... | American Society of Hematology

Table 3.

K_AV, B_max, and IC₅₀of autoantibodies from patients with iPAP

Patient	K_AVavidity, pM	B_maxcapacity, sites/mol IgG	IC₅₀, mol/mol rhGM-CSF
1	20.1	0.129	5.84
2	13.3	0.153	4.43
3	16.7	0.168	3.83
4	24.9	0.253	6.65
5	11.1	0.134	8.66
6	24.8	0.332	6.65
7	12.1	0.194	2.42
8	15	0.184	11.88
9	22.3	0.565	2.42
10	37	0.273	12.08
11	22.3	0.281	12.69
Average ± SD	19.96 ± 7.54	0.24 ± 0.13	7.05 ± 3.81
Commercialized goat anti—GM-CSF^*	275.4	0.402	74.91
Commercialized murine anti—GM-CSF^*	ND	ND	> 4000

Patient	K_AVavidity, pM	B_maxcapacity, sites/mol IgG	IC₅₀, mol/mol rhGM-CSF
1	20.1	0.129	5.84
2	13.3	0.153	4.43
3	16.7	0.168	3.83
4	24.9	0.253	6.65
5	11.1	0.134	8.66
6	24.8	0.332	6.65
7	12.1	0.194	2.42
8	15	0.184	11.88
9	22.3	0.565	2.42
10	37	0.273	12.08
11	22.3	0.281	12.69
Average ± SD	19.96 ± 7.54	0.24 ± 0.13	7.05 ± 3.81
Commercialized goat anti—GM-CSF^*	275.4	0.402	74.91
Commercialized murine anti—GM-CSF^*	ND	ND	> 4000

ND indicates not determined.

Neutralizing antibodies.